Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience
- 15 December 2016
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 24 (6) , 464-471
Abstract
Summary: Limited data are available on direct‐acting antivirals for treating hepatitis C virus (HCV) infection in patients with severe renal impairment. The aim of this study was to evaluate the effectiveness and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) ± dasabuvir (DSV) ± ribavirin (RBV) in patients with stage 4 or 5 chronic kidney disease (CKD) and HCV genotype 1 or 4 infection in real clinical practice, and to investigate pharmacological interactions. This retrospective study included patients treated with OBV/PTV/r+DSV±RBV or OBV/PTV/r+RBV with CKD stage 4 (eGFR: 15‐29 mL/min/1.73m2) or 5 (eGFR2 or requiring dialysis) and HCV infection by genotypes 1 and 4 between April 2015 and October 2015 in nine Spanish centres. Sustained virological response at 12 weeks (SVR12) was assessed, and clinical and laboratory data, fibrosis stage, adverse events and pharmacological interactions were reported. Forty‐six patients were included: 10 (21.7%) had CKD stage 4 and 36 (78.2%) CKD stage 5. Seventeen (36.9%) had cirrhosis. SVR12 rate in the intention‐to‐treat population was 95.7%. Twenty‐one (45.6%) received RBV, which was discontinued in two (9.5%) patients. Anaemia (haemoglobin P=.246). Renal function remained stable during antiviral therapy. Nine patients (19.5%) experienced serious adverse events unrelated to antiviral therapy. Concomitant medication was discontinued or modified in 41.3% of patients. In conclusion, the effectiveness of OBV/PTV/r±DSV±RBV in patients with CKD 4‐5 was similar to that observed in those with normal renal function and was not associated with severe adverse events.Keywords
This publication has 25 references indexed in Scilit:
- ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b InfectionGastroenterology, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCVNew England Journal of Medicine, 2014
- ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with CirrhosisNew England Journal of Medicine, 2014
- Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with RibavirinNew England Journal of Medicine, 2014
- Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1New England Journal of Medicine, 2014
- Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalenceHepatology, 2013
- Hepatitis C and Renal Disease: Epidemiology, Diagnosis, Pathogenesis and Therapy2012
- Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C PatientsClinical Journal of the American Society of Nephrology, 2011
- Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration RateAnnals of Internal Medicine, 2006